Phospho-JAK3 (Tyr785) antibodies are essential tools for studying the activation and regulation of Janus kinase 3 (JAK3), a tyrosine kinase critical in cytokine receptor signaling, particularly in immune cells. JAK3 is predominantly expressed in hematopoietic cells and associates with the common gamma chain (γc) of cytokine receptors, such as those for IL-2. IL-4. IL-7. IL-9. IL-15. and IL-21. Its activation occurs via transphosphorylation upon ligand-receptor binding, with Tyr785 being a key autophosphorylation site that stabilizes kinase activity and facilitates downstream signaling through the JAK-STAT pathway.
Phospho-specific antibodies targeting Tyr785 enable researchers to detect JAK3 activation status in cellular models or tissues, aiding in the study of immune regulation, hematopoiesis, and pathological conditions like autoimmune diseases or cancers. Dysregulated JAK3 signaling, often linked to mutations or constitutive phosphorylation, is implicated in disorders such as T-cell leukemia and severe combined immunodeficiency (SCID). These antibodies are validated for techniques like Western blotting, immunoprecipitation, and immunofluorescence, often using stimulated cell lysates (e.g., IL-2-treated lymphocytes) as positive controls.
Research using Phospho-JAK3 (Tyr785) antibodies contributes to understanding JAK3's role in therapeutic contexts, including the development of JAK inhibitors for inflammatory diseases. Specificity is critical, as cross-reactivity with other JAK family members (JAK1. JAK2. TYK2) must be ruled out to ensure accurate data interpretation.